ATE273320T1 - Fusogene liposomen - Google Patents
Fusogene liposomenInfo
- Publication number
- ATE273320T1 ATE273320T1 AT97915236T AT97915236T ATE273320T1 AT E273320 T1 ATE273320 T1 AT E273320T1 AT 97915236 T AT97915236 T AT 97915236T AT 97915236 T AT97915236 T AT 97915236T AT E273320 T1 ATE273320 T1 AT E273320T1
- Authority
- AT
- Austria
- Prior art keywords
- fusogenic liposomes
- liposomes
- virosomal
- virosomes
- liposomal
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title abstract 2
- 230000000799 fusogenic effect Effects 0.000 title 1
- 108091005461 Nucleic proteins Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000000277 virosome Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1529296P | 1996-04-11 | 1996-04-11 | |
| PCT/CA1997/000245 WO1997038010A2 (en) | 1996-04-11 | 1997-04-10 | Fusogenic liposomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE273320T1 true ATE273320T1 (de) | 2004-08-15 |
Family
ID=21770580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97915236T ATE273320T1 (de) | 1996-04-11 | 1997-04-10 | Fusogene liposomen |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6417326B1 (de) |
| EP (1) | EP0910576B1 (de) |
| AT (1) | ATE273320T1 (de) |
| AU (1) | AU2284697A (de) |
| CA (1) | CA2252055C (de) |
| DE (1) | DE69730218D1 (de) |
| WO (1) | WO1997038010A2 (de) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030113347A1 (en) * | 1991-05-08 | 2003-06-19 | Schweiz. Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| ATE273320T1 (de) | 1996-04-11 | 2004-08-15 | Univ British Columbia | Fusogene liposomen |
| WO1998051278A2 (en) * | 1997-05-14 | 1998-11-19 | Inex Pharmaceuticals Corporation | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| GB9721901D0 (en) * | 1997-10-16 | 1997-12-17 | Univ Manchester | Particles |
| AU1656799A (en) * | 1997-12-12 | 1999-07-05 | Inex Pharmaceuticals Corp. | Cationic drugs encapsulated in anionic liposomes |
| IL126681A0 (en) * | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
| US7094423B1 (en) * | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
| US20050249794A1 (en) * | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
| JP2004508012A (ja) * | 2000-04-20 | 2004-03-18 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法 |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| GB0100196D0 (en) * | 2001-01-04 | 2001-02-14 | Anmat Technology Ltd | Peptides |
| JP2004533421A (ja) | 2001-03-27 | 2004-11-04 | バイオミラ，インコーポレイテッド | Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン |
| EP1852126B1 (de) * | 2001-03-27 | 2013-05-15 | Oncothyreon Inc. | Impfstoff zur Modulation zwischen T1 und T2 Immunantworten |
| US20030077829A1 (en) * | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| EP1441763A2 (de) * | 2001-11-07 | 2004-08-04 | Inex Pharmaceuticals Corp. | Mukosale adjuvantien, die ein oligonukleotid und ein kationisch lipid enthält |
| US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
| US20040009944A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
| US20060193905A1 (en) * | 2002-05-14 | 2006-08-31 | University Of Louisville Research Foundation, Inc. | Direct cellular energy delivery system |
| US7056529B2 (en) * | 2002-05-14 | 2006-06-06 | University Of Louisville Research Foundation, Inc. | Direct cellular energy delivery system |
| SI1551876T1 (sl) | 2002-10-16 | 2011-07-29 | Purdue Pharma Lp | Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo |
| US20070112176A1 (en) * | 2003-04-04 | 2007-05-17 | Daiichi Pharmaceutical Co., Ltd. | Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| JP5107573B2 (ja) * | 2003-04-25 | 2012-12-26 | ザ ペン ステイト リサーチ ファウンデーション | 増殖抑制性脂質由来生物活性化合物の全身送達方法およびシステム |
| TWI329130B (en) * | 2003-06-19 | 2010-08-21 | Bestewil Holding Bv | Functionally reconstituted viral membranes containing adjuvant |
| WO2005032593A1 (ja) * | 2003-10-01 | 2005-04-14 | Japan Science And Technology Agency | 核移行能を有するポリアルギニン修飾リポソーム |
| JP2007509040A (ja) * | 2003-10-11 | 2007-04-12 | イネックス ファーマシューティカルズ コーポレイション | 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物 |
| US20050214356A1 (en) * | 2004-03-24 | 2005-09-29 | Joyce Timothy H | Self assembling activation agents targeted using active drug release |
| TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| CA2821167C (en) | 2004-05-03 | 2016-06-28 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| JP4692983B2 (ja) * | 2004-07-12 | 2011-06-01 | 独立行政法人科学技術振興機構 | リポソーム封入物質がエンドソームから脱出可能なリポソーム |
| US20080051323A1 (en) * | 2004-08-21 | 2008-02-28 | Kosak Kenneth M | Chloroquine drug compositions and methods for their synthesis |
| US20060045910A1 (en) * | 2004-09-02 | 2006-03-02 | Ehringer William D | Preserved fusogenic vesicles |
| US20060134189A1 (en) * | 2004-11-17 | 2006-06-22 | Protiva Biotherapeutics, Inc | siRNA silencing of apolipoprotein B |
| JP5364371B2 (ja) | 2005-06-28 | 2013-12-11 | オンコセリオン インコーポレイテッド | ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法 |
| WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
| WO2008105178A1 (ja) * | 2007-02-28 | 2008-09-04 | National University Corporation Hokkaido University | リポソーム用生体成分抵抗性増強剤及びこれにより修飾されたリポソーム |
| KR100890317B1 (ko) * | 2008-05-08 | 2009-03-26 | 고려대학교 산학협력단 | 플라티늄 항암제 조성물 및 제제 |
| EP2123258A1 (de) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomen zur Arzneimittelverabreichung |
| CA2730737A1 (en) * | 2008-07-15 | 2010-01-21 | Novartis Ag | Immunogenic amphipathic peptide compositions |
| WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
| US8236943B2 (en) | 2009-07-01 | 2012-08-07 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
| PL3338765T3 (pl) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
| WO2012031043A1 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| CN105193724A (zh) | 2011-02-24 | 2015-12-30 | 肿瘤防护公司 | 含有佐剂的以muc1 为基础的糖脂肽疫苗 |
| JP5850915B2 (ja) * | 2011-03-14 | 2016-02-03 | 国立大学法人北海道大学 | 肺送達のためのベクター、導入剤及び使用 |
| AU2012242455A1 (en) * | 2011-04-15 | 2013-11-28 | Molecular Transfer, Inc. | Agents for improved delivery of nucleic acids to eukaryotic cells |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| WO2013066903A1 (en) | 2011-10-31 | 2013-05-10 | Mallinckrodt Llc | Combinational liposome compositions for cancer therapy |
| US9080144B2 (en) * | 2012-05-10 | 2015-07-14 | Muhammad Naveed Yousaf | Compositions and methods for promoting liposomal and cellular adhesion |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| EP2912045A4 (de) * | 2012-10-29 | 2016-07-13 | Molecular Transfer Inc | Polykationische methylphospholipide zur verbesserten freisetzung von nukleinsäuren in eukaryotischen zellen |
| US8999925B2 (en) * | 2013-02-26 | 2015-04-07 | The Administrators Of The Tulane Educational Fund | Arenavirus inhibiting peptides and uses therefor |
| ES2981185T3 (es) | 2013-03-14 | 2024-10-07 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
| EP2968586B1 (de) | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Cftr-mrna-zusammensetzungen und zugehörige verfahren sowie verwendungen |
| WO2014197991A1 (en) | 2013-06-12 | 2014-12-18 | Muhammad Yousaf | Compounds for promoting liposomal and cellular adhesion and compositions and methods of use thereof |
| US11224642B2 (en) | 2013-10-22 | 2022-01-18 | Translate Bio, Inc. | MRNA therapy for argininosuccinate synthetase deficiency |
| MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
| EP2910239A1 (de) * | 2014-02-20 | 2015-08-26 | Universitat Autònoma De Barcelona | Neue Zusammensetzungen aus lipidbeschichteten Bakteriophagen |
| JP6571679B2 (ja) | 2014-04-25 | 2019-09-04 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| US9968683B2 (en) | 2014-12-17 | 2018-05-15 | Organolinx Corp. | Method for conjugating molecules |
| AU2016340153B2 (en) | 2015-10-16 | 2022-06-02 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| CN105801668B (zh) * | 2016-04-01 | 2020-08-07 | 天津大学 | 一种寡聚精氨酸修饰的磷脂与其组装的纳米粒及制备方法和应用 |
| EP3538546B1 (de) | 2016-11-14 | 2025-01-08 | Novartis AG | Zusammensetzungen, methoden und therapeutische verwendungen des fusogenen proteins minion |
| AU2018224326B2 (en) | 2017-02-27 | 2024-01-04 | Translate Bio, Inc. | Novel codon-optimized CFTR mRNA |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| CN111356448A (zh) * | 2017-09-18 | 2020-06-30 | 北卡罗莱纳州立大学 | 人工β细胞及其使用方法 |
| US10849924B2 (en) | 2017-09-26 | 2020-12-01 | New York Medical College | Compositions and methods for restoring endothelial glycocalyx |
| CN118421617A (zh) | 2018-08-24 | 2024-08-02 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
| EP3883592A1 (de) | 2018-11-21 | 2021-09-29 | Translate Bio, Inc. | Behandlung von zystischer fibrose durch verabreichung von vernebelter mrna, die cftr codiert |
| WO2021055609A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| WO2023231959A2 (en) | 2022-05-30 | 2023-12-07 | Shanghai Circode Biomed Co., Ltd | Synthetic circular rna compositions and methods of use thereof |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| WO2024102677A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Circular rna compositions |
| WO2025101976A1 (en) * | 2023-11-09 | 2025-05-15 | Mercury Bio, Inc. | Chimeric yeast extracellular vesicles for the enhanced delivery of therapeutic molecules to cells |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4814798B1 (de) * | 1968-12-26 | 1973-05-10 | ||
| DE2455623C3 (de) | 1974-11-23 | 1981-04-23 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von N-Acylaminocarbonsäurepoyläthylenglykolestern |
| JPH0816066B2 (ja) * | 1986-07-18 | 1996-02-21 | エーザイ株式会社 | 持続性薬効製剤 |
| JP2893191B2 (ja) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
| FR2658521B1 (fr) | 1990-02-19 | 1994-01-21 | Serbioo | Bipeptides symetriques comportant un reste polyalkyleneglycol, procede de preparation et utilisation dans le dosage des proteases. |
| JP2604268B2 (ja) * | 1990-04-09 | 1997-04-30 | 富士写真フイルム株式会社 | ペプチド誘導体両親媒性化合物、その中間体、ペプチド誘導体両親媒性化合物を用いたリポソームおよび薄膜 |
| US5372807A (en) | 1990-05-14 | 1994-12-13 | University Of Medicine And Dentistry Of New Jersey | Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use |
| US5229366A (en) | 1990-10-23 | 1993-07-20 | Fuji Photo Film Co., Ltd. | Peptide-containing polyethylene glycol derivatives and application thereof |
| JPH04208296A (ja) * | 1990-11-30 | 1992-07-29 | Fuji Photo Film Co Ltd | ペプチド誘導体 |
| US5652274A (en) * | 1991-03-01 | 1997-07-29 | Martin; Alain | Therapeutic-wound healing compositions and methods for preparing and using same |
| JPH04297494A (ja) * | 1991-03-26 | 1992-10-21 | Fuji Photo Film Co Ltd | ペプチド誘導体とその用途 |
| GB9120653D0 (en) | 1991-09-27 | 1991-11-06 | Procter & Gamble | Dispensing agent |
| WO1993022343A1 (en) | 1992-05-01 | 1993-11-11 | The Rockfeller University | Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5693609A (en) * | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| ATE273320T1 (de) | 1996-04-11 | 2004-08-15 | Univ British Columbia | Fusogene liposomen |
-
1997
- 1997-04-10 AT AT97915236T patent/ATE273320T1/de not_active IP Right Cessation
- 1997-04-10 US US08/835,281 patent/US6417326B1/en not_active Expired - Fee Related
- 1997-04-10 AU AU22846/97A patent/AU2284697A/en not_active Abandoned
- 1997-04-10 CA CA002252055A patent/CA2252055C/en not_active Expired - Fee Related
- 1997-04-10 DE DE69730218T patent/DE69730218D1/de not_active Expired - Lifetime
- 1997-04-10 EP EP97915236A patent/EP0910576B1/de not_active Expired - Lifetime
- 1997-04-10 WO PCT/CA1997/000245 patent/WO1997038010A2/en not_active Ceased
-
2002
- 2002-06-05 US US10/164,967 patent/US7205273B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20030125517A1 (en) | 2003-07-03 |
| WO1997038010A3 (en) | 1998-02-05 |
| WO1997038010A2 (en) | 1997-10-16 |
| CA2252055A1 (en) | 1997-10-16 |
| DE69730218D1 (de) | 2004-09-16 |
| CA2252055C (en) | 2007-01-16 |
| US6417326B1 (en) | 2002-07-09 |
| EP0910576B1 (de) | 2004-08-11 |
| US7205273B2 (en) | 2007-04-17 |
| EP0910576A2 (de) | 1999-04-28 |
| AU2284697A (en) | 1997-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69730218D1 (de) | Fusogene liposomen | |
| DE69832293D1 (de) | Zubereitungen zur abgabe von negativ geladenen molekülen | |
| FI950887A7 (fi) | MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt | |
| DE69534778D1 (en) | Cathepsin-02-protease | |
| BR0207775A (pt) | Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização | |
| ATE270557T1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
| NO993257D0 (no) | N-acylfosfatidyletanolaminformidlet liposomal legemiddelavlevering | |
| ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
| DE69823046D1 (de) | Praktische in vitro sialylierung von rekombinanten glykpproteinen | |
| AUPP589598A0 (en) | Novel peptides | |
| ATE295722T1 (de) | Zielgerichtete liposomen zur verabreichung von genen | |
| EE03619B1 (et) | Süsivesik-modifitseeritud tsütostaatikumid | |
| MX9806041A (es) | Proteina purificada sr-p70. | |
| ATE345778T1 (de) | (ester)-lysolecithine in liposomen | |
| MY138219A (en) | Biologically active peptides | |
| EA199900750A1 (ru) | Водная фармацевтическая композиция, включающая активный ингредиент, в высшей степени нерастворимый в воде | |
| ATE214708T1 (de) | Kationische mittel zur transfektion von nukleinsäuren | |
| TR200001055T2 (tr) | Yeni metilenbifosfonik asit türevleri | |
| DE69726602D1 (en) | Hepatitis b inhibitoren | |
| WO2002044195A3 (en) | Method for base sequencing and biologically active nucleic acids | |
| ATE299704T1 (de) | Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril | |
| DE60219601D1 (de) | Durch liposome vermittelte dna verabreichung | |
| IT1298437B1 (it) | Procedimento per la produzione di proteine/peptidi tossici | |
| GR980100008A (el) | Πολυδιαστατο μοριακο ενδοστηριγμα στην υλη | |
| ZA9811804B (en) | 11ß-halogen-7Ó-substituted estratrienes, process for the production of pharmaceutical preparations that contain these 11ß-halogen-7Ó-substituted estratrienes as well as their use for the production of pharmaceutical agents. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |